David Meek appointed CEO of Ipsen

David Meek appointed CEO of Ipsen

It was announced yesterday that David Meek has been appointed CEO of Ipsen in a statement released by the board of the French pharmaceutical group.

The US-born Meek has held numerous management positions in large pharmaceutical groups in the biotechnology sector, including recently holding the position of Executive Vice President and then President of the Oncology division with Baxalta.

 

The appointment will take effect from the 18th of July and Marc de Garidel, the former CEO, will exercise the function of non-executive Chairman while continuing to serve on the board.

 

David Meek holds a bachelor’s degree in management from the University of Cincinnati and began his career at Johnson & Johnson before joining Novartis in 2005 and then Endocyte between 2012 and 2014. Mr Meek next career move will now see him take his place at the headquarters of Ipsen, in Boulogne-Billancourt, near Paris.

 

Marc de Garidel expressed his excitement at the announcement of the news, saying:

 

“I particularly welcome the arrival of David Meek in our group. David is a visionary leader who has earned a reputation for strong expertise in the pharmaceutical and biotechnology industry worldwide.

His experience in the US, Europe and international markets as well as his deep knowledge of the world of oncology will be very valuable. David also led successful business development related activities, which will be an asset to achieving our strategic goals.

David will continue the priority tasks of the Group’s internationalization, our leadership on targeted diseases and strengthen our pipeline. I am confident that David will bring to our team a new look, a new momentum, and help accelerate the sustainable growth of the group ”

 

Mr Meek himself also expressed his pleasure at being appointed to the chair at Ipsen, stating:

 

“I am very honoured and excited to join as CEO of Ipsen, a pharmaceutical company experiencing strong growth, which has significant opportunities to increase its leadership in specialty medicine and general medicine.

 

I am proud and motivated to lead the Ipsen teams, whose great skill and commitment to patients is well-known. My ambition is to focus the group’s attention on innovation for patient care and lead the Ipsen teams to continue the success story begun by Marc de Garidel in 2010. “